In Vancouver, British Columbia, Canada, T-Ray Science Inc. has announced milestones toward the commercialization of its detection technology for skin cancer. The medical device company has signed a research agreement with the Skin Care Centre at Vancouver General Hospital and the University of British Columbia, received a Health Canada ruling that will simplify the approval process for the Verisante Aura multimodality imaging and spectroscopy system for skin cancer detection, and signed a lease for a manufacturing facility in Richmond, British Columbia. The announcements indicate progress toward bringing to market the benefits of the Aura system, which include better patient outcomes, system-wide cost savings and immediate diagnoses.